作者: Lutz Eric , Charles J Yeo , Keith D Lillemoe , Barbara Biedrzycki , Barry Kobrin
DOI: 10.1097/SLA.0B013E3181FD271C
关键词: Survival rate 、 Cancer research 、 GVAX 、 Pancreatic cancer 、 Medicine 、 Adenocarcinoma 、 T cell 、 Pancreatic disease 、 Immunology 、 Immunotherapy 、 Pancreatic tumor
摘要: Pancreatic cancer remains the fourth leading cause of related death in United States.1 Surgical resection provides only possibility cure. However, historical 5-year survival postresection approximately 15% to 20%, with 1 and 2-year 63% 42% respectively.2 A standard adjuvant treatment approach for patients resected disease has not yet been determined.2–11 We developed irradiated GM-CSF transfected allogeneic whole cell tumor lines pancreas ductal adenocarcinoma immunotherapy.12 We previously reported that this immunotherapy administered intradermally sequence chemoradiotherapy pancreatic induced posttreatment delayed type hypersensitivity (DTH) responses autologous cells 3 participants receiving × 108 2 5 vaccine cells. The DTH responders are who remain disease-free at 10+ years. Importantly, immunized lymphocytes from DTH-responders were used screen a number differentially expressed genes cancer. All demonstrated postimmunotherapy T response mesothelin, glycosyl-phosphatidylinositol (GPI)-linked surface protein likely serves as an adhesion molecule promotes metastases.13–16 We now report results single institution 60 patient phase II study testing highest dose secreting found be safe bioactive I testing. This was designed estimate overall rates prevalence mesothelin-specific associated treatment.